Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS)‘s stock had its “overweight” rating reiterated by analysts at Piper Jaffray Companies in a note issued to investors on Wednesday. They presently have a $30.00 target price on the specialty pharmaceutical company’s stock. Piper Jaffray Companies’ price objective points to a potential upside of 35.50% from the stock’s current price.

Several other equities research analysts have also issued reports on ADMS. Mizuho reaffirmed a “buy” rating and set a $26.00 price target on shares of Adamas Pharmaceuticals in a research note on Tuesday, June 6th. Zacks Investment Research raised Adamas Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, July 11th. BidaskClub lowered Adamas Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, July 19th. Cowen and Company set a $45.00 price target on Adamas Pharmaceuticals and gave the stock a “buy” rating in a research note on Wednesday, August 9th. Finally, Noble Financial reaffirmed a “buy” rating on shares of Adamas Pharmaceuticals in a research note on Wednesday, August 9th. One analyst has rated the stock with a sell rating, two have given a hold rating and six have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $36.14.

Shares of Adamas Pharmaceuticals (NASDAQ:ADMS) traded up 2.07% during trading on Wednesday, reaching $22.14. The company’s stock had a trading volume of 667,986 shares. The stock’s 50-day moving average is $19.52 and its 200-day moving average is $17.50. Adamas Pharmaceuticals has a 12-month low of $12.10 and a 12-month high of $23.84. The stock’s market cap is $498.46 million.

Adamas Pharmaceuticals (NASDAQ:ADMS) last issued its quarterly earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.93) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.81) by ($0.12). The business had revenue of $0.02 million during the quarter, compared to analysts’ expectations of $0.03 million. During the same period in the prior year, the business posted ($0.78) earnings per share. The firm’s revenue was down 90.9% on a year-over-year basis. Equities research analysts anticipate that Adamas Pharmaceuticals will post ($3.77) earnings per share for the current fiscal year.

WARNING: “Adamas Pharmaceuticals, Inc. (ADMS) Stock Rating Reaffirmed by Piper Jaffray Companies” was originally published by American Banking News and is the property of of American Banking News. If you are viewing this report on another website, it was illegally copied and republished in violation of U.S. and international copyright law. The original version of this report can be accessed at https://www.americanbankingnews.com/2017/10/04/adamas-pharmaceuticals-inc-adms-stock-rating-reaffirmed-by-piper-jaffray-companies-2.html.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its holdings in shares of Adamas Pharmaceuticals by 10.3% in the first quarter. Vanguard Group Inc. now owns 716,419 shares of the specialty pharmaceutical company’s stock worth $12,537,000 after buying an additional 66,825 shares during the period. Goldman Sachs Group Inc. increased its holdings in shares of Adamas Pharmaceuticals by 212.9% in the first quarter. Goldman Sachs Group Inc. now owns 60,897 shares of the specialty pharmaceutical company’s stock worth $1,066,000 after buying an additional 41,436 shares during the period. Emerald Advisers Inc. PA increased its holdings in shares of Adamas Pharmaceuticals by 2.7% in the second quarter. Emerald Advisers Inc. PA now owns 532,727 shares of the specialty pharmaceutical company’s stock worth $9,317,000 after buying an additional 14,042 shares during the period. Geode Capital Management LLC increased its holdings in shares of Adamas Pharmaceuticals by 4.9% in the first quarter. Geode Capital Management LLC now owns 125,793 shares of the specialty pharmaceutical company’s stock worth $2,201,000 after buying an additional 5,920 shares during the period. Finally, Granite Point Capital Management L.P. increased its holdings in shares of Adamas Pharmaceuticals by 11.9% in the second quarter. Granite Point Capital Management L.P. now owns 263,515 shares of the specialty pharmaceutical company’s stock worth $4,609,000 after buying an additional 28,000 shares during the period. Hedge funds and other institutional investors own 69.31% of the company’s stock.

Adamas Pharmaceuticals Company Profile

Adamas Pharmaceuticals, Inc is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues.

Analyst Recommendations for Adamas Pharmaceuticals (NASDAQ:ADMS)

Receive News & Ratings for Adamas Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.